Association of Hyperapobetalipoproteinemia with Endogenous Hypertriglyceridemia and Atherosclerosis
Overview
Affiliations
Researchers disagree on whether plasma triglyceride levels are an independent risk factor for atherosclerotic coronary artery disease. We hypothesized that patients with endogenous hypertriglyceridemia would differ: Some would have normal values of plasma low-density lipoprotein (LDL) B protein; others, despite their normal level of LDL cholesterol, would have increased levels of LDL B protein. We believe the latter patients--those with hyperapobetalipoproteinemia--would be the ones at risk for atherosclerosis. We studied two populations. Group 1, consisting of 162 patients with type IV lipoprotein patterns, was divided into two groups. One subgroup (A), which included 38 patients with elevated plasma LDL B atherosclerotic disease than the other subgroup (B) of 36 patients with normal levels of plasma LDL B protein (10 patients versus two, p less than 0.02). Group 2 consisted of 100 patients who had had myocardial infarction. Eighty-one percent of the 47 hypertriglyceridemic and 70% of the 53 normotriglyceridemic patients had elevated plasma LDL B protein levels (129 mg/dL or greater)--a proportion significantly higher than that in Group 1 (p less than 0.001). Thus, an elevated plasma level of LDL B protein not only identifies subgroups of patients with type IV lipoprotein patterns, but also may be an important marker for atherosclerotic disease.
Gomez-Hernandez A, de Las Heras N, Lopez-Pastor A, Garcia-Gomez G, Infante-Menendez J, Gonzalez-Lopez P Cells. 2021; 10(8).
PMID: 34440804 PMC: 8392327. DOI: 10.3390/cells10082035.
Nurtazina A, Kozhakhmetova D, Dautov D, Shakhanova A, Chattu V Diagnostics (Basel). 2020; 10(8).
PMID: 32717783 PMC: 7459610. DOI: 10.3390/diagnostics10080510.
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
Sniderman A, Thanassoulis G, Glavinovic T, Navar A, Pencina M, Catapano A JAMA Cardiol. 2019; 4(12):1287-1295.
PMID: 31642874 PMC: 7369156. DOI: 10.1001/jamacardio.2019.3780.
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.
Sniderman A, Couture P, Martin S, DeGraaf J, Lawler P, Cromwell W J Lipid Res. 2018; 59(7):1266-1275.
PMID: 29769239 PMC: 6027915. DOI: 10.1194/jlr.R082271.
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.
Berglund L, Brunzell J, Goldberg A, Goldberg I, Sacks F, Murad M J Clin Endocrinol Metab. 2012; 97(9):2969-89.
PMID: 22962670 PMC: 3431581. DOI: 10.1210/jc.2011-3213.